Immediate Impact
30 standout
Citing Papers
Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients
2024 Standout
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
2024 Standout
Works of C. Velter being referenced
The ABC of Hidradenitis Suppurativa: A Validated Glossary on how to Name Lesions
2016
Four cases of rituximab-associated melanoma
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| C. Velter | 138 | 71 | 45 | 64 | 31 | 262 | |
| Burcu Barutçuoğlu | 55 | 81 | 24 | 35 | 32 | 295 | |
| David S. Nurse | 119 | 33 | 56 | 20 | 29 | 267 | |
| Lin Cai | 67 | 83 | 20 | 25 | 27 | 292 | |
| Frédérick Durand | 57 | 31 | 31 | 52 | 31 | 314 | |
| Chakshu Gupta | 57 | 77 | 77 | 56 | 26 | 309 | |
| Robert S. Lester | 97 | 87 | 51 | 17 | 21 | 309 | |
| F. Poizeau | 115 | 36 | 44 | 33 | 29 | 275 | |
| Pearl Pai | 50 | 22 | 36 | 67 | 34 | 287 | |
| Claudia Lasagni | 167 | 43 | 27 | 60 | 28 | 316 | |
| Tsutomu Takahashi | 18 | 37 | 68 | 36 | 35 | 317 |
All Works
Login with ORCID to disown or claim papers
Loading papers...